Howe Jolanda sold $194K of MIRM
Howe Jolanda (SVP, GLOBAL CONTROLLER) sold 1,840 shares of Mirum Pharmaceuticals, Inc. (MIRM) at $105.29 ($0.19M total) on 2026-08-03 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the officer’s open-market sale size, price, and that it was executed under a pre-arranged 10b5-1 plan. The text does not include any new corporate, clinical, regulatory, or financial catalyst.
Market read
Traders may note the insider sale for sentiment, but the 10b5-1 designation and lack of other catalysts limit tradable impact.
What to watch
The article provides only the sale details; it does not include option exercises, purchases, or net insider activity, which can matter more than a single sale.
Background
The article is an SEC Form 4 insider transaction disclosure for Mirum Pharmaceuticals, Inc.
Ticker impact
Mirum Pharmaceuticals disclosed an SVP global controller open-market sale of 1,840 shares at $105.29 on a 10b5-1 plan.
Low near-term impact; any reaction is likely muted and short-lived unless accompanied by other news.
The filing is a Form 4 for an officer sale under a pre-arranged 10b5-1 plan, with no accompanying guidance, operational update, or regulatory/financial event in the text.
Market effects
No sector read-through provided; this is company-specific insider activity.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can still be interpreted by some traders as a lack of conviction, especially if it coincides with other negative signals not mentioned here.
Key entities
- issuerMirum Pharmaceuticals, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderHowe Jolanda
SVP, Global Controller who sold 1,840 shares under a 10b5-1 plan.
